Soligenix, Inc. announced that it has appointed Oreola Donini, PhD, as its Vice President of Preclinical Research and Development. Dr. Donini has more than 13 years experience in drug discovery and preclinical development with start-up biotechnology companies and has been instrumental in leading early stage development of several novel therapies into the clinic. Dr. Donini has worked previously with ESSA Pharma Inc., Inimex Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc., developing novel therapies for infectious disease, cancer and cancer supportive care.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.35 USD | -2.51% | -10.85% | -53.78% |
23/05 | Sector Update: Health Care Stocks Retreat Late Afternoon | MT |
23/05 | Sector Update: Health Care Stocks Lower Thursday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.78% | 51.13L | |
+12.19% | 12TCr | |
+12.49% | 11TCr | |
-9.08% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-15.52% | 1.63TCr | |
+6.09% | 1.41TCr | |
+28.99% | 1.2TCr |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix Appoints Oreola Donini as Vice President of Preclinical Research and Development